677 results on '"Yong, Wei‐Peng"'
Search Results
152. A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.
153. Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.
154. The chemo-brain effect in colorectal cancer patients.
155. Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC).
156. 675 INTRA-PERITONEAL PACLITAXEL IN COMBINATION WITH SYSTEMIC XELOX FOR GASTRIC CANCER WITH PERITONEAL METASTASES: RESULTS FROM A SINGAPOREAN PHASE II TRIAL
157. 590 AN ORGANOID-IMMUNE CELL CO-CULTURE PREDICTIVE MODEL TO TARGET HER2/PD-L1 POSITIVE GASTRIC CANCERS
158. An Organoid Approach to Target Her2/PD‐L1 Positive Gastric Cancers
159. Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions.
160. Safety and tolerability of oxaliplatin based pressurized intraperitoneal aerosol chemotherapy (PIPAC) for patients with peritoneal carcinomatosis: A phase I dose-finding study in Asian patients.
161. Targeted therapeutics-oriented tumor classification: a paradigm shift
162. The role of pharmacogenetics in cancer therapeutics
163. Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions
164. An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models
165. A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).
166. Prospective validation of a serum miRNA panel for early detection of gastric cancer.
167. A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).
168. AB046. P-14. TREETOPP: a phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs)
169. AB063. P-34. A multicenter, phase 1b/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment naïve advanced or metastatic biliary tract cancer (BTC)
170. AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions
171. A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).
172. Single-cell analysis of immune-microenvironment and immune-tumor interaction in human gastric cancers.
173. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
174. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
175. Predictors of survival outcome following radical gastrectomy for gastric cancer
176. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma
177. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial
178. A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs
179. The Role of Liver-Directed Therapy in Metastatic Colorectal Cancer
180. Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis
181. Validation of a LC-MS/MS Method for Quantitative Analysis of MELK Inhibitor OTS167 in Mouse Serum: Application to a Pharmacokinetic Study
182. A Sensitive Liquid Chromatography-tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study
183. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
184. TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).
185. Clinical outcome and prognostic factors for Asian patients treated in a phase I study at the National University Cancer Institute, Singapore (NCIS).
186. Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.
187. Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy
188. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
189. Resisting resistance to cancer immunotherapy
190. Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling
191. Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases.
192. Tweak to Treat: Reprograming Bacteria for Cancer Treatment
193. The topography of DNA methylation in the non-neoplastic colonic mucosa surrounding colorectal cancers
194. Numerical Simulation on the Influence of Mining-Induced Fractures Field on Gas Drainage and its Application
195. Theory and test research on permeability of coal and rock body influenced by mining
196. Abstract B035: Evaluation of a novel monoclonal antibody targeting ASC amino acid transporter 2 using patient-derived xenograft mouse models of gastric cancer
197. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β
198. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer
199. Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study
200. Chemotherapy for advanced gastric cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.